Catalio Capital Management — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
BiotechSouth San Francisco, US
Watson Debi(Director)Anne Rubin(Executive Officer, Director)Kirsten Angela Macfarlane(Executive Officer, Director, Promoter)Cameron Wheeler(Director)Randall Olson(Director)Robert Jackson(Director)
Co-investorsCatalio Capital Management, LPBraidwellDeerfield Management CompanyGV (Google Ventures)Johnson & Johnson Innovation – JJDC
Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.
BiotechHealthtechMedical DevicesRedwood City, US
Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)inRoy Maute(Cofounder & Chief Executive Officer)in
BoardJacob Vogelstein(Director)Steven Gillis(Director)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPAlexandria
HealthtechCambridge, US
Rahul Dhanda(Executive Officer, Director)James Collins(Director)David Walt(Director)in
BoardIssi Rozen(Director)in
Co-investorsCatalio Capital Management, LPIllumina VenturesGood VenturesGV (Google Ventures)Northpond VenturesNovalis LifeSciences
BiotechHealthtechDurham, US
Xiling Shen(Executive Officer, Director, Promoter)David Shiaowen(Director)William Roy Smythe(Executive Officer, Director)
BoardAlaa Halawa(Director)John de Koning(Director)
Co-investorsAlexandriaAlix VenturesEQT Life SciencesFelicis VenturesMC Healthcare VenturesMubadala Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.